Bookmark and Share

$LXRP Remains Ahead of the Pack with Innovative Delivery Technology

Biotechnology company Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP) is the developer of the drug-delivery platform DehydraTECH(TM). The company’s innovative technology promotes healthier ingestion methods, lower overall dosing and higher effectiveness of lipophilic active molecules. An article discussing the company reads, “One of the delivery challenges is the amount of CBD waste created, because the human body can only absorb a small amount of the molecules. DehydraTECH is disrupting this cycle by protecting the product during stomach transit, amplifying intestinal absorption by five to ten times over traditional methods and enabling the drug to bypass first-pass liver metabolism. Third-party lab studies have shown a 15- to 20-minute onset of THC effects in humans when using the edible tech. . . . Products that use the DehydraTECH drug-delivery platform have been shown to deliver CBD faster than those that use medium-chain triglyceride oils. A recent study reported a 319% higher CBD blood concentration at 60 minutes when using the DehydraTECH formulation as opposed to coconut oil (http://nnw.fm/Cs2DX). Fatty acids used with DehydraTECH have the added benefit of masking the bitter taste of CBD, allowing a better overall experience for the consumer without the need for added sugars or chemicals.”

To view the full article, visit: http://nnw.fm/t37mM

About Lexaria Bioscience Corp.

Lexaria Bioscience Corp. licenses disruptive, patented-delivery technology that promotes healthier ingestion methods, lower overall dosing and higher effectiveness of lipophilic active molecules. Lexaria has multiple patents pending in over 40 countries around the world and has patents granted in the United States and Australia for utilization of its DehydraTECH delivery technology. Lexaria’s technology provides increases in intestinal absorption rates, more rapid delivery to the bloodstream, and important taste-masking benefits for orally administered bioactive molecules including cannabinoids, vitamins, nonsteroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules. For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LXRP are available in the company’s newsroom at http://nnw.fm/LXRP

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive instant SMS alerts, text STOCKS to 77948

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

Tuesday, July 23rd, 2019 Uncategorized